aibioModerna MRNA offering and convertible notes news
Top story · Sep 1, 2026 · SEC filing 8-K
Moderna sells unregistered shares
The Company relied on these exemptions from registration based in part on representations made by the initial purchasers in the purchase agreement dated August 27, 2026 by and among the Company and the representatives of the initial purchasers.
- Ticker
- MRNA
- Listing
- NASDAQ, United States
- Next date
- October 23-27, 2026
- Chief executive
- Stéphane Bancel
Desk view · Opinion · Updated Oct 22, 2026
Moderna's cancer bet pays off in phase 3; now it has to make and market it
Moderna now has a credible cancer product and new money to launch it, after a positive phase 3 melanoma trial and a $2.6 billion note sale. The vaccine business still loses money, and the full intismeran data and manufacturing plan will decide how much the cancer bet is worth.
Read the full desk viewaibio.space Investor Rank · Opinion
7/10 Positive view
Intismeran's positive phase 3 and new financing support the cancer pivot, but the vaccine business loses money, revenue is small and cash is shrinking.
- Technology
- 2/2
- Odds
- 2/2
- Balance sheet
- 1/2
- Risk
- 1/2
- Momentum
- 1/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven in vaccines, now in cancer. Intismeran met its phase 3 melanoma goal, the first positive phase 3 for an mRNA cancer therapy.
- Odds
- Favorable for intismeran. Base rates put approval near 91% once filed, though the size of the benefit is not yet public.
- Balance sheet
- Large but shrinking. $6.9 billion at June 30, then a $950 million settlement payment and a $2.6 billion convertible sale.
- Main risk
- Cash burn and launch execution. Vaccine sales are seasonal, and each intismeran dose is made for one patient.
- Watch next
- ESMO, October 23 to 27. Full INTerpath-001 data will show how large the melanoma benefit is.
Top news on Moderna
- Debt Financing
Moderna sells $3.0 billion of zero-coupon convertible notes after upsized pricing
The notes convert at about $210.58 a share, 47.5% above the August 27 close, and proceeds may fund the oncology business.
- Debt Financing
Moderna plans $2.0 billion convertible notes private placement
Moderna said it intends to sell $2.0 billion of notes due 2032, with an option for up to $300.0 million more. It would also enter capped call transactions to reduce potential dilution.
Questions investors ask
What is aibio.space's Investor Rank for Moderna?
7 out of 10, our positive view. Intismeran's positive phase 3 and new financing support the cancer pivot, but the vaccine business loses money, revenue is small and cash is shrinking. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
Did Moderna's cancer vaccine work in phase 3?
Yes. Merck and Moderna said on August 19, 2026, that the phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary endpoint of recurrence-free survival in resected high-risk melanoma. Hazard ratios have not been released. Source
Is Moderna's flu vaccine approved?
Yes. The FDA approved mFLUSIVA on August 5, 2026, for people aged 50 and older. In its phase 3 trial it showed 26.6% relative efficacy against a standard-dose flu vaccine. Source
How much cash does Moderna have?
Moderna reported $6.9 billion in cash, cash equivalents and investments at June 30, 2026. It then paid a $950 million settlement in July and priced $2.6 billion of convertible notes in August. Source
What are the terms of Moderna's 2032 convertible notes?
The $2.6 billion of notes pay no regular interest, mature March 1, 2032, and convert at about $210.58 per share. Moderna bought capped calls with a cap price of about $392.62 to reduce dilution. Source
When will Moderna present the full intismeran melanoma data?
The INTerpath-001 results are scheduled as late-breaking abstract LBA1 in the Presidential Symposium at the ESMO Congress in Madrid, which runs October 23 to 27, 2026. Source
What is the latest Moderna (MRNA) stock news?
Our latest story on Moderna, dated Aug 28, 2026: "Moderna sells $3.0 billion of zero-coupon convertible notes after upsized pricing". The notes convert at about $210.58 a share, 47.5% above the August 27 close, and proceeds may fund the oncology business. Source
What is Moderna's market cap?
We do not publish live share prices. In its annual report, Moderna, Inc. put the market value of shares held by non-affiliates (public float) at $9.90 billion as of Jun 30, 2025. Source
Is Moderna a smaller reporting company?
SEC records list Moderna, Inc.'s filer category as: Large accelerated filer. Source
Where is Moderna headquartered?
SEC records list its business address as 325 BINNEY STREET, CAMBRIDGE, MA, 02142. Source
When does Moderna's fiscal year end?
Moderna, Inc.'s fiscal year ends on December 31, per SEC records. Source
What did Moderna last file with the SEC?
Its most recent filing in our record is an 8-K filed 2026-09-30. All of its filings are on SEC EDGAR. Source
What was Moderna called before?
SEC records list these former names: Moderna Therapeutics, Inc.. Source
What industry is Moderna in?
Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source
How can I follow Moderna (MRNA) news?
Press Follow on this page to add Moderna to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Moderna so far, in Debt Financing. Source
Legal and investor matters
- Financing
Moderna completes $3.0 billion convertible notes offering
On 2026-09-01 Moderna completed a private offering of $3,000,000,000 of 0.00% Convertible Senior Notes due 2032, including the initial purchasers' full exercise of an option for $400,000,000 more. The notes are senior unsecured obligations and mature on 2032-03-01 unless converted, redeemed or repurchased. They carry no regular interest, though special interest can accrue in circumstances set out in the indenture.
- Litigation
Moderna settles Arbutus and Genevant patent litigation for $950 million
On 2026-03-03 Moderna settled all worldwide patent litigation with Arbutus Biopharma and Genevant Sciences over Spikevax and mRESVIA, including the case in the District of Delaware. Moderna agreed to a $950 million noncontingent lump sum, with no future royalties owed. The 10-Q filed 2026-07-31 says Moderna has appealed a Section 1498 ruling to the Federal Circuit and could owe a further payment of up to $1.3 billion depending on that appeal.
- Litigation
GSK patent suits against Moderna proceed in Delaware and European courts
The 10-K filed 2026-02-20 reports that GSK sued Moderna in October 2024 in the District of Delaware over its COVID and RSV vaccines, alleging willful infringement of lipid-mRNA formulation patents. Trials are set for 2027-07-19 (COVID) and 2027-08-23 (RSV). GSK also filed two Unified Patent Court suits in July 2025 and Spanish suits served in December 2025. The 10-K gives no damages estimate.
- Derivative suit
Shareholder derivative suits over RSV vaccine statements: stayed per 10-K, pending per 10-Q
Between September and November 2024, purported shareholders filed derivative complaints in the District of Massachusetts against certain Moderna officers and directors, with Moderna as nominal defendant. The complaints allege breaches of fiduciary duty and Exchange Act claims over statements about the RSV vaccine mRNA-1345. The 10-K filed 2026-02-20 says the cases were stayed pending a ruling on the motion to dismiss the related securities class action.
- Regulatory
FDA issues refusal-to-file letter for Moderna flu vaccine mRNA-1010
Moderna said the FDA's Center for Biologics Evaluation and Research notified it on 2026-02-03 that it would not initiate review of the biologics license application for the investigational seasonal influenza vaccine mRNA-1010 and had issued a refusal-to-file letter. In the 10-Q filed 2026-07-31, Moderna refers to the FDA's ongoing review of its BLA for mRNA-1010 and a unanimous advisory committee vote.
- Litigation
Moderna patent suits against Pfizer and BioNTech: mixed rulings in U.S. and Europe
Moderna sued Pfizer and BioNTech in 2022 over mRNA COVID vaccines. The Massachusetts case is stayed after the PTAB found two asserted patents invalid in March 2025, which Moderna appealed. In the UK the Court of Appeal upheld the '949 patent in August 2025 and the Supreme Court denied permission to appeal in December 2025. A European Patent Office board confirmed the '565 patent invalid on 2026-01-27.
- Financing
Moderna signs $1.5 billion credit facility with Ares Capital
On 2025-11-19 Moderna entered a credit and guaranty agreement with Ares Capital Corporation as administrative and collateral agent. The $1.5 billion facility has a $600 million initial term loan and $900 million of delayed draw term loans, part of which depends on regulatory milestones. Loans accrue interest at Term SOFR plus 5.50% and mature on 2030-11-24.
- Class action
Moderna moves to dismiss securities class action over RSV vaccine statements
A putative shareholder class action was filed in August 2024 in the District of Massachusetts against Moderna and certain officers. It was brought for purchasers of Moderna stock and asserts Exchange Act claims over statements about the RSV vaccine mRNA-1345. An amended complaint filed 2025-08-25 narrowed the class period to 2024-02-15 through 2024-05-31. Moderna moved to dismiss on 2025-10-24, and the 10-K filed 2026-02-20 says that motion remains pending.
- Litigation
Moderna and Alnylam settle patent disputes, no payment by Moderna
Moderna and Alnylam agreed on 2025-09-15 to settle all disputes between them, including a stipulated dismissal of Alnylam's claims with prejudice. The agreement followed a June 2025 Federal Circuit decision in Moderna's favor in Alnylam's cationic lipid patent suits in the District of Delaware. The 10-K filed 2026-02-20 states that the settlement did not include payments of any kind by Moderna.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Intismeran autogene (mRNA-4157), with Merck | Adjuvant melanoma (plus Keytruda); lung, kidney, bladder cancer | Phase 3 met primary endpoint (melanoma); other trials phase 2/3 Source |
| mFLUSIVA (mRNA-1010) | Seasonal influenza, ages 50 and older | FDA approved August 5, 2026 Source |
| mCOMBRIAX (mRNA-1083) | Flu plus COVID-19 combination | Approved in EU; awaiting FDA guidance on U.S. refiling Source |
| mRNA-3927, with Recordati | Propionic acidemia | Registrational study, enrollment reached Source |
| mRNA-1403 | Norovirus | Phase 3 (missed interim early-success bar; adding cohort) Source |
Opinion · Devil's advocate
Fact-check-o-meter
Moderna's releases are accurate on the facts, but the biggest open questions sit in the 10-Q and the missing trial numbers
The Q2 release matches the 10-Q on what happened. The gaps are omissions: the release did not mention the up to $1.3 billion further payment the 10-Q says Moderna could be required to make depending on the outcome of its appeal in the Arbutus and Genevant matter, and the melanoma announcement gave no hazard ratio or event counts. The 10-Q also discloses a pending shareholder class action tied to RSV vaccine statements, which is a documented matter, not a finding.
Press release vs filing · weight high
Settlement release omits the possible extra $1.3 billion
The company said: "The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026." source
The record says: The 10-Q says Moderna has "appealed the District Court's decision related to 28 U.S.C. § 1498 to the Federal Circuit Court of Appeals and could be required to make an additional payment of up to $ 1.3 billion depending on the outcome of the appeal. As of June 30, 2026, no accrual has been recorded for this amount as a loss is not considered probable." source
Our view: The release reports the $950 million as paid and does not mention the appeal. The 10-Q shows a contingent payment larger than the $950 million already paid, and the release's year-end cash range of $4.7 to $5.2 billion does not refer to it. A reader of the release alone would not see it.
Press release vs filing · weight medium
Phase 3 melanoma win announced without effect size
The company said: "At a pre-specified interim analysis, intismeran in combination with KEYTRUDA as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone" source
The record says: The same release says "the study will continue in order to evaluate other key secondary endpoints, including overall survival (OS)" and that data "will be presented at an upcoming international medical meeting". It gives no hazard ratio, event count or median follow-up. ClinicalTrials.gov lists RFS as the primary outcome and DMFS and overall survival as secondary outcomes for NCT05933577. source
Our view: The result is a topline from an interim analysis. Until the numbers are shown, "clinically meaningful" is the sponsors' judgment, and overall survival is still ahead.
Science · weight medium
The 49% figure comes from an open-label phase 2b trial
The company said: "reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone" source
The record says: ClinicalTrials.gov lists KEYNOTE-942 (NCT03897881) as phase 2, randomized, masking "NONE" with the description "Open Label", and 267 actual participants. The phase 3 trial (NCT05933577) is double blind with an estimated 1,089 participants. source
Our view: The 49% number is from a smaller, unmasked trial. It is the only effect size the Q2 release cites for the combination, and the phase 3 topline gave no comparable number.
Legal and disclosure record · weight medium
Pending shareholder class action and patent suits disclosed
The record says: Legal Proceedings in the 10-Q for the quarter ended June 30, 2026: "We are subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachusetts related to statements about our RSV vaccine (mRNA-1345)." The 10-Q also lists patent suits with Pfizer, BioNTech, GSK, Northwestern University, CureVac and Sanofi subsidiaries, among others. The filing does not give the filing date of the securities suits. source
Our view: These are matters Moderna itself reports. The filing states that no material contingent liabilities were recognized as of June 30, 2026 and does not say how the securities suits will end.
Documents we compared
Stock chart
SEC filings and registration
- SEC name
- Moderna, Inc.
- CIK
- 1682852
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- MRNA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Phone
- 6177146500
- Shares outstanding
- 399,235,889 as of 2026-07-24 (10-Q filed 2026-07-31)
- Former names
- Moderna Therapeutics, Inc.
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction